Bristol-Myers Squibb/AstraZeneca's Onglyza will garner peak year sales of more than $1 bn in the Type 2 diabetes drug market.

Decision Resources finds that, for the treatment of Type 2 diabetes, Bristol-Myers Squibb/AstraZeneca's Onglyza will garner peak year blockbuster sales of more than $1 bn in the US, France, Germany, Italy, Spain, the UK and Japan. The Pharmacor finding from the topic entitled Type 2 Diabetes reveals that, although it does not offer significant clinical benefit over Merck's Januvia, the uptake of Onglyza will be driven by its safety and tolerability, convenient administration and lack of weight gain associated with its use. Onglyza, which along with Januvia are the only two DPP-IV inhibitors approved for Type 2 diabetes in the US market, is expected to compete closely with Januvia …